Mercodia’s Lispro Northern Lights (NL)-ELISA provides a chemiluminescent method for the quantitative determination of insulin lispro.
Lispro is a rapid-acting insulin analogue that was first introduced in 1996 to treat people with diabetes. Mercodia’s Lispro NL-ELISA, a novel pharmacokinetics (PK) assay, is both sensitive and specific for determination of insulin lispro. With pre-diluted calibrators in serum matrix at six levels, as evidenced by the robust assay performance characteristics, this method is suitable for multiple phases of drug development and meets the requirements of EMA and FDA validation.
The Lispro NL-ELISA Kit enables a broad measuring range, is fully validated for use with human and porcine samples, and requires a low sample volume of 10 μL. The ELISA kit has no cross-reactivity to endogenous insulin or other insulin analogues and has no interference from insulin auto-antibodies. Additionally, the kit gives results in just 2 h 15 min.
Phone: 02 9698 2022
Siemens Healthineers 3gAllergy assay
Siemens Healthineers has expanded its 3gAllergy assay menu with nine additional component...
Navinci NaveniFlex Tissue Red proximity ligation assay kit
The kit enables fluorescence visualisation of protein–protein interactions or...
Bio-Rad Laboratories StarBright Dyes for spectral flow cytometry
The range provides users with more options when designing spectral flow cytometry panels,...
